Evolent Health, Inc (NYSE:EVH)‘s stock had its “buy” rating reaffirmed by equities research analysts at SunTrust Banks, Inc. in a research note issued to investors on Friday. They currently have a $30.00 price objective on the technology company’s stock. SunTrust Banks, Inc.’s price objective would indicate a potential upside of 126.42% from the company’s current price.

Several other equities research analysts also recently issued reports on EVH. Robert W. Baird set a $35.00 price target on Evolent Health and gave the stock a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Cowen and Company reiterated an “outperform” rating and set a $33.00 price objective (down from $35.00) on shares of Evolent Health in a report on Wednesday, August 9th. BidaskClub downgraded Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Thursday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.70.

Shares of Evolent Health (EVH) opened at $13.25 on Friday. Evolent Health has a fifty-two week low of $13.20 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.89 and a current ratio of 1.89.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.27% and a negative net margin of 15.86%. The company had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. During the same period in the prior year, the company earned ($0.26) earnings per share. The company’s revenue for the quarter was up 79.2% compared to the same quarter last year. research analysts anticipate that Evolent Health will post -0.54 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Evolent Health, Inc (EVH) Rating Reiterated by SunTrust Banks, Inc.” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/04/evolent-health-inc-evh-rating-reiterated-by-suntrust-banks-inc.html.

A number of hedge funds have recently bought and sold shares of EVH. FMR LLC grew its stake in Evolent Health by 117.7% in the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after purchasing an additional 5,333,252 shares in the last quarter. Riverbridge Partners LLC bought a new position in Evolent Health in the second quarter valued at approximately $58,878,000. Vanguard Group Inc. grew its stake in Evolent Health by 48.9% in the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after purchasing an additional 1,237,941 shares in the last quarter. Eagle Asset Management Inc. bought a new position in Evolent Health in the second quarter valued at approximately $27,577,000. Finally, Kornitzer Capital Management Inc. KS bought a new position in Evolent Health in the third quarter valued at approximately $14,258,000. Hedge funds and other institutional investors own 89.64% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.